Vaksin BCG: The Hidden Shield Against Deadly Diseases

Published 20 February 2026

The first dose of vaksin BCG is often administered within days of birth, marking one of the earliest medical interventions in a human life. Unlike many vaccines that target specific pathogens, this inoculation carries a dual legacy: it was developed to combat tuberculosis (TB), yet its mechanisms extend far beyond. Decades of research reveal that vaksin BCG doesn’t just prime the immune system against Mycobacterium tuberculosis—it reshapes it, offering unintended protections against unrelated infections and even certain cancers. This paradox makes it a subject of both historical reverence and modern scientific intrigue.

In regions where TB remains endemic, vaksin BCG is administered to millions annually, its efficacy measured not just in lives saved but in the broader immune resilience it fosters. Yet in low-risk countries, its routine use has diminished, sparking debates over its necessity. The vaccine’s story is one of adaptation: from a colonial-era remedy to a tool in cutting-edge immunotherapy, its journey reflects broader shifts in global health priorities. Understanding its full scope requires examining not only its direct benefits but also the indirect ways it influences immunity across a lifetime.

What makes vaksin BCG uniquely compelling is its dual identity—as both a preventive measure and a biological modulator. While it remains the cornerstone of TB control in high-burden settings, studies now suggest it may reduce severe outcomes in respiratory infections, diabetes complications, and even autism spectrum disorders. This duality raises critical questions: Should its use be expanded beyond TB-endemic areas? How do its long-term effects on the immune system compare to other vaccines? And what does its future hold as researchers explore its potential in treating autoimmune diseases and cancer?

The Complete Overview of Vaksin BCG

The vaksin BCG (Bacillus Calmette-Guérin) stands as one of the oldest vaccines still in widespread use, first administered in 1921 following nearly a decade of development by French bacteriologists Albert Calmette and Camille Guérin. Derived from a live, attenuated strain of Mycobacterium bovis, the vaccine was designed to provide immunity against Mycobacterium tuberculosis, the bacterium responsible for tuberculosis. Unlike many modern vaccines that rely on weakened or inactivated pathogens, vaksin BCG uses a closely related but less virulent strain to trigger a controlled immune response. This approach not only protects against TB but also induces trained immunity—a phenomenon where the immune system becomes "trained" to respond more vigorously to subsequent infections, regardless of their cause.

Today, vaksin BCG is administered to an estimated 100 million infants annually, primarily in countries with high TB incidence. The World Health Organization (WHO) recommends its use in newborns, particularly in regions where TB is prevalent, though its efficacy varies by strain and geographic context. What distinguishes vaksin BCG from other vaccines is its off-target effects: while its primary goal is TB prevention, research increasingly highlights its broader immunologic benefits. These include reduced mortality from sepsis in preterm infants, lower risk of respiratory infections in early childhood, and potential protective effects against autoimmune conditions like type 1 diabetes. This multifaceted role has positioned vaksin BCG as a subject of intense study in both infectious disease and immunology.

Historical Background and Evolution

The origins of vaksin BCG trace back to the early 20th century, when tuberculosis was a leading cause of death worldwide. Calmette and Guérin began their work in 1908 by cultivating Mycobacterium bovis in a bile-salt medium, gradually attenuating its virulence over 230 serial passages—a process that took nearly a decade. The resulting strain, named BCG (for Bacillus Calmette-Guérin), was first tested in humans in 1921 on a newborn in Paris, marking the beginning of its global dissemination. By the 1930s, vaksin BCG was being used in Europe and the United States, though its adoption was met with skepticism due to inconsistent efficacy in clinical trials. Despite this, the vaccine gained traction in countries with high TB burdens, particularly in Africa and Asia, where it became a public health staple.

Post-World War II, the WHO endorsed vaksin BCG as a critical tool in TB eradication efforts, leading to mass vaccination campaigns. However, variations in vaccine strains—due to differences in production methods and passage history—resulted in disparities in efficacy. Some strains, like the Danish 1331 and the Tokyo 172 strains, demonstrated higher effectiveness in preventing severe TB forms, particularly in children. These inconsistencies prompted ongoing research into strain optimization, genetic stability, and immune response variability. Today, vaksin BCG remains a cornerstone of TB control, though its role has expanded beyond TB to include non-specific immune modulation—a shift that reflects evolving understandings of immunology.

Core Mechanisms: How It Works

The protective effects of vaksin BCG stem from its ability to induce both specific and non-specific immune responses. Upon administration, the live attenuated Mycobacterium bovis strain colonizes local tissues, particularly the skin or mucous membranes, where it triggers a robust innate immune reaction. This includes the activation of macrophages, natural killer (NK) cells, and the release of pro-inflammatory cytokines like TNF-α and IL-12. The vaccine also stimulates a T-cell-mediated response, with CD4+ and CD8+ T cells producing interferon-gamma (IFN-γ), which is crucial for containing mycobacterial infections. Unlike killed vaccines, vaksin BCG persists in the body for months, continuously stimulating immune memory—a feature that contributes to its long-lasting effects.

Beyond TB-specific immunity, vaksin BCG induces "trained immunity," a phenomenon where the innate immune system undergoes metabolic and epigenetic reprogramming. This trained state enhances the body’s ability to respond to unrelated pathogens, such as viruses and bacteria causing sepsis or respiratory infections. Studies suggest that vaksin BCG may also modulate autoimmune responses by skewing the immune system toward a more regulatory phenotype, potentially reducing the risk of conditions like type 1 diabetes and multiple sclerosis. This dual functionality—specific protection against TB and broad immune training—explains why vaksin BCG continues to be studied not just as a vaccine but as a potential therapeutic agent in immunology.

Key Benefits and Crucial Impact

The primary benefit of vaksin BCG lies in its role as the most effective tool against TB in children, where it reduces the risk of severe forms like miliary TB and meningitis by up to 80%. In high-burden countries, this translates to hundreds of thousands of lives saved annually. However, its impact extends far beyond TB. Epidemiological studies in regions with universal vaksin BCG coverage have shown lower childhood mortality rates from non-TB causes, including respiratory infections and neonatal sepsis. This "off-target" protection is attributed to the vaccine’s ability to enhance innate immune function, a discovery that has reshaped perceptions of its value in global health.

Beyond direct health outcomes, vaksin BCG plays a critical role in public health infrastructure. Its widespread use has facilitated the development of cold chain logistics and immunization programs, serving as a model for other vaccines. Additionally, the vaccine’s low cost and ease of administration make it accessible in low-resource settings, where TB remains a major health threat. Yet, its broader potential—particularly in training the immune system against emerging pathogens—is only beginning to be explored. As researchers uncover new layers of its immunologic effects, vaksin BCG may transition from a TB-specific tool to a broader immune modulator with applications in oncology and autoimmune disease management.

"The BCG vaccine is more than a tool against tuberculosis; it is a biological reset button for the immune system, capable of reprogramming how we respond to challenges long after the initial dose."

— Dr. Mihai Netea, Radboud University Medical Center

Major Advantages

• TB Prevention in Children: Reduces the risk of severe TB forms (e.g., meningitis, miliary TB) by 50–80% in high-burden settings, with the highest efficacy in the first two years of life.
• Non-Specific Immune Training: Lowers mortality from unrelated infections (e.g., sepsis, respiratory syncytial virus) by enhancing innate immune memory—a phenomenon known as "trained immunity."
• Autoimmune Modulation: Emerging evidence suggests vaksin BCG may reduce the risk of type 1 diabetes and other autoimmune conditions by promoting immune regulation.
• Oncologic Potential: Preclinical studies indicate that vaksin BCG may enhance anti-tumor immunity, particularly in bladder cancer treatments where it is already used as an intravesical therapy.
• Logistical and Economic Viability: Low production cost, stability at room temperature, and ease of administration make it ideal for mass vaccination campaigns in resource-limited settings.

Comparative Analysis

Future Trends and Innovations

The next decade of vaksin BCG research is likely to focus on harnessing its trained immunity effects for broader applications. Current trials are investigating its potential to reduce mortality in preterm infants, where sepsis remains a leading cause of death. Additionally, studies exploring vaksin BCG in combination with other vaccines—such as those for influenza or COVID-19—aim to enhance cross-protection against respiratory pathogens. The vaccine’s role in oncology is also gaining traction, with ongoing investigations into its ability to prime the immune system for checkpoint inhibitor therapies in cancer patients.

Innovations in vaccine production may further optimize vaksin BCG. Genetic engineering techniques could stabilize its efficacy across different strains, while novel delivery methods (e.g., oral or mucosal administration) might improve accessibility. As our understanding of trained immunity deepens, vaksin BCG could evolve from a TB-specific tool into a platform for developing next-generation immune-boosting therapies. The challenge lies in balancing its traditional use with these emerging applications, ensuring that its full potential is realized without compromising its proven benefits.

Conclusion

Vaksin BCG remains a testament to the enduring impact of public health interventions. From its inception as a TB-fighting tool to its current status as a biological modulator with far-reaching implications, its story reflects the dynamic nature of medical science. While its primary role in TB control remains critical, the discovery of its non-specific immune effects has opened new avenues for research. The vaccine’s ability to train the immune system offers a paradigm shift in how we approach infectious diseases and autoimmune conditions, potentially paving the way for personalized immunotherapies.

As global health priorities evolve, the future of vaksin BCG will depend on its adaptability. Whether used in its traditional capacity or repurposed for novel applications, its legacy is secure. For now, it stands as a reminder that some of the most powerful medical breakthroughs are those that defy narrow definitions—protecting not just against one disease, but against the broader vulnerabilities of the human immune system.

Comprehensive FAQs

Q: Is vaksin BCG safe for all infants, including preterm babies?

A: Vaksin BCG is generally considered safe for preterm infants, though its administration may be delayed in very low birth weight babies (<1,500g) due to higher risks of disseminated BCG disease. Studies suggest that even preterm infants benefit from its non-specific immune effects, but individual risk assessments are recommended.

Q: Why does the efficacy of vaksin BCG vary by strain?

A: The efficacy of vaksin BCG depends on the specific strain used, which can vary in genetic stability and immunogenicity. For example, the Danish 1331 strain has shown higher protection against TB in some trials compared to the Tokyo 172 strain. These differences arise from variations in passage history and manufacturing processes, which affect the vaccine’s ability to induce a strong immune response.

Q: Can vaksin BCG be given alongside other vaccines?

A: Yes, vaksin BCG can be administered simultaneously with other vaccines, including DTP, hepatitis B, and oral polio vaccine. However, it is typically given intradermally in the upper arm, while other vaccines may be administered in the thigh. There is no evidence of interference between vaksin BCG and other childhood immunizations.

Q: Does vaksin BCG provide lifelong immunity against TB?

A: No, vaksin BCG does not provide lifelong immunity. While it offers strong protection in early childhood, its efficacy wanes over time, particularly in adults. Booster doses are not routinely recommended, but research into new TB vaccines (e.g., MVA85A) aims to improve long-term protection.

Q: How does vaksin BCG work in bladder cancer treatment?

A: In bladder cancer, vaksin BCG is used as an intravesical therapy, where the vaccine is instilled directly into the bladder to stimulate a local immune response. The live attenuated bacteria trigger an inflammatory reaction that helps the immune system target and destroy precancerous or cancerous cells lining the bladder. This approach is distinct from its use as a systemic vaccine for TB.

Q: Are there any long-term side effects of vaksin BCG?

A: Serious side effects from vaksin BCG are rare but can include localized infections (e.g., lymphadenitis) or, in immunocompromised individuals, disseminated BCG disease. Most common reactions are mild, such as redness or swelling at the injection site. Long-term studies have not identified significant adverse effects beyond these immediate responses.

Q: Could vaksin BCG be used to combat future pandemics?

A: Emerging research suggests that vaksin BCG’s trained immunity effects could enhance resistance to unrelated infections, including viral pathogens like influenza or SARS-CoV-2. While not a direct antiviral vaccine, studies in healthcare workers and older adults have shown reduced respiratory infection rates following vaksin BCG administration. This makes it a candidate for adjunctive use during pandemics, though further trials are needed.

• imunisasi-tbc
• imunitas-bawaan
• imunologi
• kesehatan publik
• tuberculosis
• vaksin-bcg
• vaksin-global
• vaksin-live-attenuated
• vaksinasi bayi
• vaksinasi-pencegahan